ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced full-year 2025 financial and operational highlights, including approximately $113 million in net product ...
Americans love science and revere innovation, almost as a rule, and politicians of every stripe have spent the better part of a century promoting and protecting both. However imperfect the resulting ...
ANKTIVA net product revenue increased 20% quarter-over-quarter, with full-year net product revenue of $113 million, representing an approximately 700% increase year-over-year ...
A clinical trial hosted by Memorial Sloan Kettering Cancer Center shows promising results for pancreatic cancer patients. The trial combines two primary intervention strategies to see how patients ...